Results 81 to 90 of about 2,795 (144)

Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis. [PDF]

Adv Ther
Geiger JM, Brady BL, Lew CR, Jennings M, Mo C, Van Brunt K, Dezube R.   +6 more
europepmc   +1 more source

Toward Precision Electrochemical Sensing of CFTR Function in Cystic Fibrosis Models. [PDF]

Anal Chem
Miglione A, Blaconà G, Singh S, Cicero SL, Fuso A, Cimino G, Eramo A, Malapelle U, Lucarelli M, Cinti S.   +9 more
europepmc   +1 more source

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry. [PDF]

ERJ Open Res
Dillenhöfer S, Schütz K, Burkhart M, Ellemunter H, Kappler M, Sieber S, Naehrlich L, Brinkmann F, Sutharsan S.   +8 more
europepmc   +1 more source

Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators. [PDF]

Pediatr Pulmonol
Gallardo R, Silva BS, Salgado LS, Ribeiro JD, Sakano E.   +4 more
europepmc   +1 more source

Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators. [PDF]

Acta Paediatr
Svedberg M, Lundqvist F, Östrand HA, Krantz C, Ekman P, Imberg H.   +5 more
europepmc   +1 more source

Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database. [PDF]

Front Pediatr
Chen J, Zhao L.
europepmc   +1 more source

Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]

Int J Mol Sci
Sankararaman S, Liu R, Sun X, Retuerto M, Schindler T, Roesch E, Sferra TJ, Drumm M, Ghannoum M, Zhang L.   +9 more
europepmc   +1 more source

Sinonasal and Pulmonary Computed Tomography Images Before and After Triple-Combination Therapy in a Patient with Cystic Fibrosis Without ΔF508 Mutations. [PDF]

Diagnostics (Basel)
Tagliati C, Campagna G, Di Sabatino M, Lanni G, Battista D, Ripani P.   +5 more
europepmc   +1 more source

Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Eur Respir J
Nussstein H, Urbantat RM, Fentker K, Loewe A, Duerr J, Haji M, Doellinger F, Stahl M, Graeber SY, Gradzielski M, Röhmel J, Mertins P, Schaupp L, Mall MA.   +13 more
europepmc   +1 more source

Advances in cystic fibrosis: CFTR modulator triple combinations. [PDF]

Eur Respir J
Burgel PR, Mall MA.
europepmc   +1 more source